News
Zai Lab announces first patient treated in Greater China in PANOVA-3 phase III pivotal trial.
Zai Lab Limited a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase III pivotal trial of Tumor Treating Fields in patients with pancreatic cancer.
PANOVA-3 is a global, open-label, randomized Phase III trial evaluating the efficacy of Tumor Treating Fields administered concomitantly with gemcitabine and nab-paclitaxel as front-line treatment for patients with unresectable, locally advanced pancreatic cancer. The trial is expected to enroll approximately 556 patients. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, resectability rate, and toxicity.
Condition: Pancreatic Cancer
Type: drug